U.S. pharmaceutical company Amgen is set to invest approximately $200 million this year in its new technology center in southern India, with additional investments in the pipeline, as announced by CEO Robert Bradway during the inauguration on Monday.
Last year, Amgen unveiled plans to establish a "technology and innovation" hub in India dedicated to leveraging AI and data science for the development of new medications.
Bradway expressed, "We have long aimed to expand Amgen's presence in India, and now is the opportune time. Amgen's initial investment of $200 million in this center in 2025 will be complemented by further substantial investments in the coming years."
The Hyderabad-based facility is anticipated to employ around 2,000 individuals by the end of the year, with 300 staff members already in place, according to Som Chattopadhyay, Amgen's National Executive in India.
This week, Hyderabad will host the BioAsia conference, featuring discussions by executives from pharmaceutical companies such as Amgen, Eli Lilly, Novartis, and various Indian pharmaceutical leaders.
Amgen is just one of the many global pharmaceutical companies aiming to expand their operations in India, recognized as the "pharmacy of the world."
This month, India and the U.S. initiated discussions to secure an early trade agreement and address tariff-related disputes following talks between U.S. President Donald Trump and Indian Prime Minister Modi.
According to U.S. Consul General in Hyderabad, Jennifer Larson, one significant outcome of these talks was the launch of the U.S.-India trust initiative, aimed at fostering collaboration in crucial and emerging technologies, essential for both countries.
Larson noted, "Amgen's decision to enhance its presence here exemplifies how our nations can collaborate to harness innovation, talent, and technology."
Trump has indicated intentions to impose "25% or higher" tariffs on pharmaceutical imports, a move concerning Indian firms as the U.S. represents a primary market for numerous generic drug manufacturers.